Willey Joshua Z, Gavalas Michael V, Trinh Pauline N, Yuzefpolskaya Melana, Reshad Garan A, Levin Allison P, Takeda Koji, Takayama Hiroo, Fried Justin, Naka Yoshifumi, Topkara Veli K, Colombo Paolo C
Departments of Neurology.
Medicine.
J Heart Lung Transplant. 2016 Aug;35(8):1003-9. doi: 10.1016/j.healun.2016.03.014. Epub 2016 Mar 30.
Stroke is one of the leading complications during continuous flow-left ventricular assist device (CF-LVAD) support. Risk factors have been well described, although less is known regarding treatment and outcomes. We present a large single-center experience on stroke outcome and transplant eligibility by stroke sub-type and severity in CF-LVAD patients.
Between January 1, 2008, and April 1, 2015, 301 patients underwent CF-LVAD (266 HeartMate II [HM I], Thoratec Corp, Pleasanton, CA; 35 HeartWare [HVAD], HeartWare International Inc, Framingham, MA). Stroke was defined as a focal neurologic deficit with abnormal neuroimaging. Intracerebral hemorrhage (ICH) definition excluded sub-dural hematoma and hemorrhagic conversion of an ischemic stroke (IS). Treatment in IS included intra-arterial embolectomy when appropriate; treatment in ICH included reversal of coagulopathy. Stroke severity was measured using the National Institutes of Health Stroke Scale (NIHSS). Outcomes were in-hospital mortality and transplant status.
Stroke occurred in 40 patients: 8 ICH (4 HM II, 4 HVAD) and 32 IS (26 HM II, 6 HVAD). Among 8 ICH patients, there were 4 deaths (50%), with NIHSS of 18.8 ± 13.7 vs 1.8 ± 1.7 in survivors (p = 0.049). Among 32 IS patients, 12 had hemorrhagic conversion and 5 were treated with intra-arterial embolectomy. There were 9 deaths (28%), with NIHSS of 16.2 ± 10.8 vs 7.0 ± 7.6 in survivors (p = 0.011). Among the 32 IS patients, 12 underwent transplant, and 1 is awaiting transplant. No ICH patients received a transplant.
In-hospital mortality after stroke is significantly affected by the initial neurologic impairment. Patients with IS appear to benefit the most from in-hospital treatment and often make sufficient recovery to be able to progress to transplant.
中风是持续血流左心室辅助装置(CF-LVAD)支持期间的主要并发症之一。风险因素已得到充分描述,尽管关于治疗和预后的了解较少。我们展示了一个大型单中心关于CF-LVAD患者中风亚型和严重程度的中风预后及移植资格的经验。
在2008年1月1日至2015年4月1日期间,301例患者接受了CF-LVAD(266例HeartMate II [HM II],Thoratec公司,加利福尼亚州普莱森顿;35例HeartWare [HVAD],HeartWare国际公司,马萨诸塞州弗雷明汉)。中风定义为伴有神经影像学异常的局灶性神经功能缺损。脑出血(ICH)的定义排除了硬膜下血肿和缺血性中风(IS)的出血性转化。IS的治疗包括在适当情况下进行动脉内取栓术;ICH的治疗包括纠正凝血障碍。使用美国国立卫生研究院中风量表(NIHSS)测量中风严重程度。结局指标为住院死亡率和移植状态。
40例患者发生中风:8例ICH(4例HM II,4例HVAD)和32例IS(26例HM II,6例HVAD)。在8例ICH患者中,有4例死亡(50%),NIHSS评分为18.8±13.7,而幸存者为1.8±1.7(p = 0.049)。在32例IS患者中,12例发生出血性转化,5例接受了动脉内取栓术。有9例死亡(28%),NIHSS评分为16.2±10.8,而幸存者为7.0±7.6(p = 0.011)。在32例IS患者中,12例接受了移植,1例正在等待移植。没有ICH患者接受移植。
中风后的住院死亡率受初始神经功能损害的显著影响。IS患者似乎从住院治疗中获益最大,并且通常恢复良好,能够进展到移植。